drugset
drugset / Trial / NCT03655873

The Study of a Selective 5-ht6 Receptor Antagonist, HEC30654AcOH,in Healthy Subjects

NCT03655873 ↗

Phase 1 Completed 43 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

This study is a safety, tolerability, and pharmacokinetics phase Ⅰstudy of a selective 5-ht6 receptor antagonist, HEC30654AcOH,in healthy subjects.This test is divided into two parts, the first part is the healthy adult subjects single ascending-dose research;The second part is the healthy adult subjects multiple ascending-dose research.

Timeline

Start
2018-11-21
Primary completion
2019-12-17
Completion
2019-12-17

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC30654AcOH Unknown 5 mg Oral
Subject HEC30654AcOH Unknown 10 mg Oral
Subject HEC30654AcOH Unknown 15 mg Oral
Subject HEC30654AcOH Unknown 30 mg Oral
Subject HEC30654AcOH Unknown 60 mg Oral
Subject HEC30654AcOH Unknown 90 mg Oral
Subject HEC30654AcOH Unknown 120 mg Oral

Indications

No indication recorded.